Abstract | BACKGROUND: Hearing is essential in child development. Cisplatin which is a common chemotherapy used in many pediatric solid- tumor protocols cause various degrees of ototoxicity. Several risk factors for cisplatininduced ototoxicity have been reported, including race and age. This study aimed to evaluate the incidence of ototoxicity and its long-term outcome in Thai pediatric solid- tumor patients receiving cisplatin and to determine the risk factors associated with hearing impairment. METHODS: A retrospective study was conducted in solid- tumor patients < 15 years old from 2007 to 2019 at Siriraj Hospital, Bangkok, Thailand. Hearing was evaluated by an audiogram and/or auditory steady-state response and the impairment was graded according to the Common Terminology Criteria for Adverse Events version 5. Grade 2 and above was considered significant hearing loss. RESULTS: CONCLUSIONS: The incidence of hearing impairment in pediatric patients receiving cisplatin is high. Regular hearing evaluation is essential for the early detection of ototoxicity. Long-term follow-up is recommended, especially in patients who have a combination of other risk factors for hearing loss.
|
Authors | Tatpong Sriyapai, Kanthong Thongyai, Kamon Phuakpet, Nassawee Vathana, Jassada Buaboonnam, Kleebsabai Sanpakit |
Journal | The Turkish journal of pediatrics
(Turk J Pediatr)
Vol. 64
Issue 3
Pg. 531-541
( 2022)
ISSN: 2791-6421 [Electronic] Turkey |
PMID | 35899566
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Adolescent
- Antineoplastic Agents
(adverse effects)
- Child
- Cisplatin
(adverse effects)
- Hearing
- Hearing Loss
(chemically induced, epidemiology)
- Humans
- Neoplasms
- Ototoxicity
(epidemiology, etiology)
- Retrospective Studies
- Thailand
(epidemiology)
|